The Latest Breaking News from FDA

House report questions FDA’s approval of Alzheimer’s drug

The Food and Drug Administration's contentious approval of a questionable Alzheimer's drug is taking another hit

WASHINGTON — A joint investigation released Thursday by House Democrats identified unusual collaboration between Food and Drug Administration officials and drugmaker Biogen, highlighting potential problems in the agency’s approval of the controversial Alzheimer’s drug Aduhelm.

The Evie smart ring targets women's health and is aiming to be FDA-approved. Movano says it will ideally cost less than $300 when it launches sometime in 2023.

Instead of a Santa Claus rally, the market continues to experience volatility at the end of the year with uncertainties surrounding the reopening of the Chinese economy and a looming recession due to seemingly unending interest rate hikes. Given this backdrop, loading up on fundamentally strong stocks Walmart (WMT), Pfizer…

House Democrats releases a report highlighting potential problems in the FDA's approval of Alzheimer's drug Aduhelm.

Alydia Health's Jada system for postpartum hemorrhage took 11 years to reach the market; being a women's health product made its road tougher.

With recent economic data showing promise, the chances of a soft landing for the economy are increasing. Hence, it could be wise to invest in fundamentally sound stocks CVS Health (CVS), Ooma (OOMA), and Neurocrine Biosciences (NBIX), which possess solid growth attributes. Read on….

Scientists are transforming pig livers to look and act like human ones, part of a quest to ease the nation's organ shortage

The agency in a memo Friday said the emergency contraception pills are not the same as abortion pills — which end a pregnancy — a fact that has long been understood in the medical community.

The Food and Drug Administration announced Friday that it will overhaul packaging labels for the emergency contraceptive pill, Plan B, that women can take after having sex to prevent a pregnancy